Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|24|1|78-83

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.24, Iss.1, 2018-03, pp. : 78-83

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genetically Modified Dendritic Cells for Cancer Immunotherapy

By  

Current Gene Therapy, Vol. 5, Iss. 6, 2005-12 ,pp. : 619-628

Bentham Science Publishers

Access to resources Recommend Favorite

MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 4, 2009-01 ,pp. : 344-352

Bentham Science Publishers

Access to resources Recommend Favorite

Genetically Engineered Stem Cells for Therapeutic Gene Delivery

By  

Current Gene Therapy, Vol. 7, Iss. 4, 2007-01 ,pp. : 249-260

Bentham Science Publishers

Access to resources Recommend Favorite

T Cell Targeted Strategies for Improved Efficacy and Safety of Specific Immunotherapy for Allergic Disease

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 12, Iss. 3, 2013-12 ,pp. : 201-222

Bentham Science Publishers

Access to resources Recommend Favorite

Life or Death of T Cells with Antigen-Specific Receptors - Using T Cells for Cancer Adoptive Immunotherapy / Gene Therapy

By  

Current Gene Therapy, Vol. 1, Iss. 3, 2001-09 ,pp. : 253-255

Bentham Science Publishers

Access to resources Recommend Favorite